Male late-onset hypogonadism: pathogenesis, diagnosis and treatment

被引:67
作者
Huhtaniemi, Ilpo [1 ]
Forti, Gianni [2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England
[2] Univ Florence, Endocrinol Unit, Dept Clin Physiopathol, I-50139 Florence, Italy
关键词
PLACEBO-CONTROLLED TRIALS; BIOAVAILABLE TESTOSTERONE LEVELS; SYMPTOMATIC ANDROGEN DEFICIENCY; BONE-MINERAL DENSITY; MIDDLE-AGED MEN; OLDER MEN; SERUM TESTOSTERONE; ELDERLY-MEN; AGING MEN; TRANSDERMAL TESTOSTERONE;
D O I
10.1038/nrurol.2011.47
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Some aging men develop a condition of suppressed serum testosterone levels, which is associated with diffuse sexual, physical and psychological symptoms. Several terms are used for this syndrome, but late-onset hypogonadism (LOH) is preferred. The diagnosis of LOH is often uncertain because symptoms (occurring in 20-40% of men) and low circulating testosterone (found in 20% of men > 70 years of age) seldom occur together. The strict diagnostic criteria for LOH include reproducibly low serum testosterone levels and sexual symptoms, including erectile dysfunction and reduced frequency of sexual thoughts and morning erections. Using these diagnostic criteria, only 2% of 40-80-year-old men have LOH. Obesity and impaired general health (including diabetes mellitus, cardiovascular and chronic obstructive pulmonary disease, and frailty) are more common reasons for low testosterone than advanced age per se. It seems logical, therefore, to begin by treating these conditions before testosterone replacement therapy is initiated. Even then, testosterone should only be used if there are no contraindications, such as unstable cardiac disease, serious prostate symptoms and high hemoglobin level. The long-term benefit of testosterone replacement therapy is uncertain, and the experimental nature of the treatment, and its associated risks, must be fully explained to the patient before treatment begins.
引用
收藏
页码:335 / 344
页数:10
相关论文
共 61 条
  • [1] Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone
    Amory, JK
    Watts, NB
    Easley, KA
    Sutton, PR
    Anawalt, BD
    Matsumoto, AM
    Bremner, WJ
    Tenover, JL
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) : 503 - 510
  • [2] Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study
    Araujo, AB
    O'Donnell, AB
    Brambilla, DJ
    Simpson, WB
    Longcope, C
    Matsumoto, AM
    McKinlay, JB
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (12) : 5920 - 5926
  • [3] Prevalence of symptomatic androgen deficiency in men
    Araujo, Andre B.
    Esche, Gretchen R.
    Kupelian, Varant
    O'Donnell, Amy B.
    Travison, Thomas G.
    Williams, Rachel E.
    Clark, Richard V.
    McKinlay, John B.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (11) : 4241 - 4247
  • [4] Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced Erythrocytosis
    Bachman, Eric
    Feng, Rui
    Travison, Thomas
    Li, Michelle
    Olbina, Gordana
    Ostland, Vaughn
    Ulloor, Jagadish
    Zhang, Anqi
    Basaria, Shehzad
    Ganz, Tomas
    Westerman, Mark
    Bhasin, Shalender
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (10) : 4743 - 4747
  • [5] Adverse Events Associated with Testosterone Administration
    Basaria, Shehzad
    Coviello, Andrea D.
    Travison, Thomas G.
    Storer, Thomas W.
    Farwell, Wildon R.
    Jette, Alan M.
    Eder, Richard
    Tennstedt, Sharon
    Ulloor, Jagadish
    Zhang, Anqi
    Choong, Karen
    Lakshman, Kishore M.
    Mazer, Norman A.
    Miciek, Renee
    Krasnoff, Joanne
    Elmi, Ayan
    Knapp, Philip E.
    Brooks, Brad
    Appleman, Erica
    Aggarwal, Sheetal
    Bhasin, Geeta
    Hede-Brierley, Leif
    Bhatia, Ashmeet
    Collins, Lauren
    LeBrasseur, Nathan
    Fiore, Louis D.
    Bhasin, Shalender
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (02) : 109 - 122
  • [6] Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years
    Behre, HM
    von Eckardstein, S
    Kliesch, S
    Nieschlag, E
    [J]. CLINICAL ENDOCRINOLOGY, 1999, 50 (05) : 629 - 635
  • [7] Biochemical endocrinology of the hypogonadal male
    Belchetz, Paul E.
    Barth, Julian H.
    Kaufman, Jean-Marc
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2010, 47 : 503 - 515
  • [8] Bhasin S, 2003, J GERONTOL A-BIOL, V58, P1002
  • [9] Bhasin S, 2003, J ANDROL, V24, P299
  • [10] Testosterone dose-response relationships in healthy young men
    Bhasin, S
    Woodhouse, L
    Casaburi, R
    Singh, AB
    Bhasin, D
    Berman, N
    Chen, XH
    Yarasheski, KE
    Magliano, L
    Dzekov, C
    Dzekov, J
    Bross, R
    Phillips, J
    Sinha-Hikim, I
    Shen, RQ
    Storer, TW
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (06): : E1172 - E1181